Get the Stockscreener App
8.45
0.24%
-0.02
Alvotech stock is traded at $8.45, with a volume of 469.27K.
It is down -0.24% in the last 24 hours and down -2.65% over the past month.
Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases.
See More
Previous Close:
$8.47
Open:
$8.48
24h Volume:
469.27K
Relative Volume:
1.52
Market Cap:
$2.80B
Revenue:
$391.87M
Net Income/Loss:
$-441.45M
P/E Ratio:
-4.5676
EPS:
-1.85
Net Cash Flow:
$-301.21M
1W Performance:
+5.30%
1M Performance:
-2.65%
6M Performance:
-31.19%
1Y Performance:
-29.41%
1-Day Range:
$8.33
$8.52
1-Week Range:
$8.15
$9.06
52-Week Range:
$7.35
$13.70
Alvotech Stock (ALVO) Company Profile
Compare ALVO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALVO
Alvotech
|
8.45 | 2.80B | 391.87M | -441.45M | -301.21M | -1.85 |
|
ZTS
Zoetis Inc
|
156.62 | 67.51B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.52 | 47.88B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.82 | 43.42B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.46 | 20.72B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
312.23 | 14.21B | 2.99B | 1.21B | 1.13B | 25.06 |
Alvotech Stock (ALVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-14-25 | Initiated | UBS | Buy |
| Jan-29-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Upgrade | Citigroup | Sell → Neutral |
| Sep-21-23 | Initiated | Barclays | Equal Weight |
| Sep-07-22 | Initiated | Morgan Stanley | Equal-Weight |
| Sep-06-22 | Downgrade | Citigroup | Buy → Sell |
| Jul-26-22 | Initiated | Citigroup | Buy |
View All
Alvotech Stock (ALVO) Latest News
Alvotech shares rise 1.95% after-hours after appointing Patrik Ling as VP of Investor Relations. - AInvest
Alvotech (NASDAQ:ALVO) Trading Up 7.1%Should You Buy? - MarketBeat
Sentiment Tools Show Shift in Trader Mood on AlvotechJuly 2025 Levels & Daily Growth Stock Tips - thegnnews.com
Alvotech Focuses On Value Over Volume As Sales Continue To Grow - insights.citeline.com
Alvotech's Strategic Expansion in Scandinavia and Its Implications for Long-Term Shareholder Value - AInvest
Alvotech appoints Patrik Ling as VP investor relations Scandinavia By Investing.com - Investing.com
Alvotech Appoints Patrik Ling as VP Investor Relations Scandinavia - Quiver Quantitative
Alvotech appoints Patrik Ling as VP Investor Relations Scandinavia. - AInvest
Alvotech appoints Patrik Ling as VP of Investor Relations Scandinavia - The Manila Times
Estee Lauder Forecasts Annual Profit Below Estimates - AInvest
Alvotech (NASDAQ:ALVO) Short Interest Down 34.3% in July - MarketBeat
Eimskip Publishes Q2 2025 Results, Sets Investor Meeting on August 27 - AInvest
$8.2M Annual Interest Savings: Biotech Alvotech Restructures $1.1B Loan After Strong Performance - Stock Titan
Alvotech (NASDAQ:ALVO) Stock: Massive Earnings Surprise Sparks Trading Frenzy - parameter.io
Alvotech (NASDAQ:ALVO) Shares Gap Up After Better-Than-Expected Earnings - MarketBeat
Alvotech (NASDAQ:ALVO) Sees Strong Trading Volume on Better-Than-Expected Earnings - MarketBeat
Bayer’s Eylea market grip set to slip as Alvotech biosimilar closes in - MSN
Soho House, GoodRx Holdings, Dayforce And Other Big Stocks Moving Higher On Monday - Benzinga
Alvotech (ALVO) Surges 11.5% on Earnings Beat and Strategic Expansion – Is This a Breakout Play? - AInvest
Screener Results Flag Alvotech as Oversold2025 Pullback Review & Reliable Volume Spike Alerts - thegnnews.com
Traders Consider Averaging Down in Alvotech Equity WarrantJuly 2025 Levels & Long-Term Growth Portfolio Plans - newsimpact.co.kr
How Alvotech stock performs during market volatilityTrade Volume Report & Stepwise Trade Signal Implementation - beatles.ru
Is There Enough Volume to Lift AlvotechWeekly Profit Recap & Stock Portfolio Risk Management - newsyoung.net
What are Alvotech’s recent SEC filings showingWeekly Loss Report & Expert Approved Trade Ideas - kangso.co.kr
What’s the analyst consensus on AlvotechIPO Watch & Low Drawdown Trading Techniques - classian.co.kr
Alvotech (NASDAQ:ALVO) Announces Earnings Results, Beats Estimates By $0.40 EPS - MarketBeat
Can Alvotech weather a recessionWeekly Gains Summary & Comprehensive Market Scan Reports - mustnews.co.kr
Alvotech Reports Strong H1 2025 Financials and Strategic Partnerships - MSN
Why Alvotech Shares Are Gaining Attention - TipRanks
Published on: 2025-08-16 00:15:42 - beatles.ru
Northland Securities Maintains Alvotech(ALVO.US) With Buy Rating, Maintains Target Price $28 - 富途牛牛
Alvotech Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Alvotech shares fall 3.13% premarket after H1 2025 earnings call. - AInvest
Alvotech Reports Strong Growth and Strategic Expansion - TipRanks
Alvotech targets 50% U.S. Humira biosimilar market share by year-end as Q2 product revenues rise 77% - MSN
Alvotech (ALVO) Expected to Announce Earnings on Wednesday - MarketBeat
Alvotech Reports Strong H1 2025 Financials and Strategic Partnerships. - AInvest
Alvotech's Q2 2025: Navigating Contradictions in Market Share, Revenue Guidance, and FDA Inspections - AInvest
Alvotech shares fall 11.44% intraday despite strong H1 2025 earnings and revenue growth. - AInvest
Alvotech Plunges 9.5% Intraday: Can This Biosimilars Powerhouse Rebound From Debt-Driven Volatility? - AInvest
Transcript : Alvotech, H1 2025 Earnings Call, Aug 14, 2025 - MarketScreener
Alvotech shares fall 2.34% premarket despite reporting strong H1 2025 earnings and product revenue growth. - AInvest
Alvotech Reports Results for the First Six Months of 2025 and Provides a Business Update - Placera.se
Alvotech shares rise 2.68% premarket after reporting strong Q2 2025 results and 200% product revenue growth. - AInvest
Alvotech's Q1 Operating Income Surpassing $28.6M: A Catalyst for Long-Term Growth in a High-Potential Biosimilars Sector? - AInvest
Alvotech Posts $28.6M H1 Operating Income, Product Revenue Rises - AInvest
Alvotech H1 operating income USD 28.639 million - MarketScreener
Alvotech (ALVO) Is Up 5.9% After Swinging to Profit in H1 2025What's Changed - simplywall.st
Alvotech's Strategic Transformation and Financial Turnaround: A High-Conviction Buy Opportunity in Biosimilars - AInvest
Alvotech (ALVO) Q2 Earnings and Revenues Beat Estimates - Yahoo Finance
Why Alvotech Shares Are Under Pressure - TipRanks
Alvotech Stock (ALVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.37%
0.37%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):